Breaking News

UCB, biOasis In Research Pact

December 3, 2012

To use Transcend technology for drug delivery to the brain

biOasis Technologies and UCB, based in Brussels, have entered into a research collaboration to evaluate biOasis’ Transcend technology for the delivery of therapeutic compounds to the brain. biOasis will conduct certain experiments using its Transcend technology as it relates to the delivery of therapeutic compounds owned by UCB for CNS disorders. Financial Terms were not disclosed.
"UCB is a highly respected biopharmaceutical company with a broad global presence and a deep pipeline. We’re very pleased to be commencing this collaboration with UCB whom we believe have some tremendous targets for our Transcend vector," said Rob Hutchison, chief executive officer, biOasis Technologies. "The interest from within the industry on our Transcend technology is clearly widening and this agreement with UCB is a prime example of that. The work will start over the next few months and carry into the New Year. We are looking forward to working with the UCB scientists to successfully achieve the objectives we have set out in agreement."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research